Selpercatinib Approved to Treat Some Adult and Pediatric Thyroid Cancers
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for adults and children 2 years and...